About us

2cureX, pioneers of 3D microtumors in cancer therapy selection, are focused on improving the outcomes of cancer treatment.

Until today, there has been no functional means to evaluate the most efficacious form of cancer treatment for the individual patient. Up to 50% of first line treatments of metastatic colorectal cancer are ineffective mainly due to tumor resistance, causing a measurable burden on clinic resources and immeasurable patient suffering.

With the IVD CE validated IndiTreat® Sensitivity Test, you can now test cancer treatments on patient derived microtumors in order to:

  • Predict tumor resistance and sensitivity to cancer drugs
  • Select the most appropriate treatment, in accordance with guidelines or off-label
  • Improve patient quality of life through in vitro testing of drug efficacy on the individual patient

IndiTreat® is a useful complement to the advances achieved in individual patient genomic characterization of tumors.

IndiTreat® is available for all EU registered clinics and laboratories and is amenable to automation.

2cureX are based in Copenhagen, Denmark with a subsidiary in Hamburg, Germany.

2cureX are listed on Nasdaq First North Growth Market (symbol: 2CUREX)

Upcoming events

December 7, 2021

CEO Fernando Andreu will present at ”Sedermeradagen Köbenhamn 2021” (Copenhagen, Denmark)

Read more

December 9, 2021

2cureX presents at HC Andersen Capital’s Virtual Growth Days (Copenhagen, Denmark)

Read more

January 20, 2022

2cureX present at Redeye Theme – Fight Cancer Seminar – Outlook 2022 (Stockholm, Sweden)

Read more

February 24, 2022

Year-End Report 2021

View previous reports

IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.